HKSE - Delayed Quote HKD
Genscript Biotech Corporation (1548.HK)
At close: 4:08 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
839,529.000
839,529.000
625,698.000
490,096.000
390,846.000
--
Cost of Revenue
429,976.000
429,976.000
321,615.000
207,578.000
134,953.000
--
Gross Profit
409,553.000
409,553.000
304,083.000
282,518.000
255,893.000
--
Operating Expense
808,623.000
808,623.000
731,839.000
651,730.000
447,886.000
--
Operating Income
-399,070.000
-399,070.000
-427,756.000
-369,212.000
-191,993.000
--
Net Non Operating Interest Income Expense
45,676.000
45,676.000
-51.000
407.000
-1,134.000
--
Pretax Income
-350,979.000
-350,979.000
-431,690.000
-517,363.000
-281,900.000
--
Tax Provision
4,142.000
4,142.000
-3,719.000
964.000
-477.000
--
Net Income Common Stockholders
-95,477.000
-95,477.000
-226,851.000
-358,712.000
-204,945.000
--
Diluted NI Available to Com Stockholders
-95,477.000
-95,477.000
-226,851.000
-358,712.000
-204,945.000
--
Basic EPS
-0.05
--
-0.11
-0.18
-0.11
-0.05
Diluted EPS
-0.05
--
-0.11
-0.18
-0.11
-0.05
Basic Average Shares
2,109,365.328
--
2,097,134.700
2,030,597.579
1,900,787.442
1,853,927.485
Diluted Average Shares
2,109,365.328
--
2,097,134.700
2,030,597.579
1,900,787.442
1,853,927.485
Rent Expense Supplemental
4,401.000
--
--
--
--
--
Total Expenses
1,238,599.000
1,238,599.000
1,053,454.000
859,308.000
582,839.000
--
Net Income from Continuing & Discontinued Operation
-95,477.000
-95,477.000
-226,851.000
-358,712.000
-204,945.000
--
Normalized Income
-118,738.550
-118,738.550
-232,938.104
-259,141.460
-211,074.611
--
Interest Income
73,186.000
73,186.000
13,218.000
2,785.000
4,298.000
--
Interest Expense
27,510.000
27,510.000
13,269.000
2,378.000
1,418.000
--
Net Interest Income
45,676.000
45,676.000
-51.000
407.000
-1,134.000
--
EBIT
-323,469.000
-323,469.000
-418,421.000
-514,985.000
-280,482.000
--
EBITDA
-249,423.000
-249,423.000
-354,173.000
-467,206.000
-247,587.000
--
Reconciled Cost of Revenue
429,976.000
429,976.000
321,615.000
207,578.000
134,953.000
--
Reconciled Depreciation
74,046.000
74,046.000
64,248.000
47,779.000
32,895.000
--
Net Income from Continuing Operation Net Minority Interest
-95,477.000
-95,477.000
-226,851.000
-358,712.000
-204,945.000
--
Total Unusual Items Excluding Goodwill
29,445.000
29,445.000
6,140.000
-136,398.000
6,140.000
--
Total Unusual Items
29,445.000
29,445.000
6,140.000
-136,398.000
6,140.000
--
Normalized EBITDA
-278,868.000
-278,868.000
-360,313.000
-330,808.000
-253,727.000
--
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
--
Tax Effect of Unusual Items
6,183.450
6,183.450
52.896
-36,827.460
10.389
--
12/31/2019 - 12/30/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2171.HK CARsgen Therapeutics Holdings Limited
4.010
0.00%
2126.HK JW (Cayman) Therapeutics Co. Ltd
1.580
-2.47%
2137.HK Brii Biosciences Limited
1.050
-1.87%
6855.HK Ascentage Pharma Group International
47.450
-0.52%
3759.HK Pharmaron Beijing Co., Ltd.
14.660
+1.66%
CTX.WA Captor Therapeutics Spolka Akcyjna
66.00
0.00%
2616.HK CStone Pharmaceuticals
1.800
+2.27%
2696.HK Shanghai Henlius Biotech, Inc.
22.400
-0.22%
9966.HK Alphamab Oncology
3.840
-4.00%
2142.HK HBM Holdings Limited
1.270
+0.79%